Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...

A major randomized trial has found that percutaneous coronary intervention is now more cost-effective than bypass grafting over 5 years of follow-up.

This post is part of the Health Affairs Blog short series, “Value Assessment: Where Do We Go Post-COVID?” The series explores what we have learned about value assessment and related issues during the ...

We constructed a decision model with a 10-year time horizon. The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ...

Please provide your email address to receive an email when new articles are posted on . Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...

For the initial evaluation of low-risk patients with stable chest pain, anatomic testing—coronary CT angiography (CTA) with or without noninvasive fractional flow reserve (FFR)—is cost-effective ...

Usual care provided 9.59 QALYs at a lifetime cost of $222,300, diet and exercise yielded 9.75 QALYs for $226,300, and semaglutide offered 10.48 QALYs at $273,500, with tirzepatide providing 10.68 ...